Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New Investment in DexCom, Inc. $DXCM

Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 28,001 shares of the medical device company’s stock, valued at approximately $1,858,000.

A number of other institutional investors have also bought and sold shares of DXCM. Holocene Advisors LP purchased a new position in DexCom in the 3rd quarter worth approximately $163,964,000. CIBC Private Wealth Group LLC lifted its stake in DexCom by 374.3% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after purchasing an additional 2,294,709 shares in the last quarter. Vanguard Group Inc. lifted its stake in DexCom by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after purchasing an additional 1,133,638 shares in the last quarter. Iron Triangle Partners LP purchased a new position in DexCom in the 3rd quarter worth approximately $57,196,000. Finally, DNB Asset Management AS lifted its stake in DexCom by 271.8% in the 3rd quarter. DNB Asset Management AS now owns 1,098,544 shares of the medical device company’s stock worth $73,921,000 after purchasing an additional 803,086 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $59.91, for a total transaction of $101,847.00. Following the sale, the executive vice president directly owned 109,504 shares in the company, valued at approximately $6,560,384.64. The trade was a 1.53% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 6,112 shares of company stock worth $379,990. Corporate insiders own 0.28% of the company’s stock.

DexCom Stock Up 0.6%

DXCM stock opened at $71.90 on Friday. The firm has a market cap of $27.74 billion, a PE ratio of 30.73, a PEG ratio of 1.18 and a beta of 1.40. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The firm’s 50 day moving average price is $63.46 and its 200-day moving average price is $65.94. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.32 EPS. On average, equities research analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. TD Cowen decreased their target price on shares of DexCom from $84.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. BTIG Research reissued a “buy” rating and issued a $85.00 target price on shares of DexCom in a research note on Monday, March 9th. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Bank of America decreased their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Robert W. Baird set a $80.00 target price on shares of DexCom in a research note on Friday, May 1st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $82.21.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.